Clinical Trials Browser

Recruiting × Non-Muscle Invasive Bladder Neoplasms × tislelizumab × Clear all

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms